NATURE MEDICINE, 30.641, Scientific Journal Selector, NATURE MEDICINE abbreviation, submission, acceptance rate, review time, editorial board, publication fee, NATURE MEDICINE
![How to Get Into Harvard Medical School: Requirements and Strategies — Shemmassian Academic Consulting How to Get Into Harvard Medical School: Requirements and Strategies — Shemmassian Academic Consulting](https://images.squarespace-cdn.com/content/v1/5269fbd3e4b0eb2b76ccc1db/1577751019290-EY3JVXDHNFFO753SL47M/ke17ZwdGBToddI8pDm48kG87Sfbgg29A4BYEDq3OXvgUqsxRUqqbr1mOJYKfIPR7LoDQ9mXPOjoJoqy81S2I8N_N4V1vUb5AoIIIbLZhVYxCRW4BPu10St3TBAUQYVKcf4OxbJOyh_wHUnyc4kQLQ6SBshRGOku7c30Y_IRDNPta8R2IY5BHMaEj1zOWoDTZ/How+To+Get+Into+Harvard+Medical+School+Shemmassian+Academic+Consulting.jpg)
How to Get Into Harvard Medical School: Requirements and Strategies — Shemmassian Academic Consulting
![Polygenic and clinical risk scores and their impact on age at onset and prediction of cardiometabolic diseases and common cancers.,Nature Medicine - X-MOL Polygenic and clinical risk scores and their impact on age at onset and prediction of cardiometabolic diseases and common cancers.,Nature Medicine - X-MOL](https://xpic.x-mol.com/20200410%2F10.1038_s41591-020-0800-0.png)
Polygenic and clinical risk scores and their impact on age at onset and prediction of cardiometabolic diseases and common cancers.,Nature Medicine - X-MOL
![Nature Medicine در توییتر "First up from 2018: #Neoadjuvant combination treatment with nivolumab and ipilimumab in patients with high-risk #melanoma results in higher response rates than nivolumab monotherapy #NMEDClinical | https://t.co/QpHRjqbFdk ... Nature Medicine در توییتر "First up from 2018: #Neoadjuvant combination treatment with nivolumab and ipilimumab in patients with high-risk #melanoma results in higher response rates than nivolumab monotherapy #NMEDClinical | https://t.co/QpHRjqbFdk ...](https://pbs.twimg.com/media/EBTbxZDXkAAWLlV.jpg)
Nature Medicine در توییتر "First up from 2018: #Neoadjuvant combination treatment with nivolumab and ipilimumab in patients with high-risk #melanoma results in higher response rates than nivolumab monotherapy #NMEDClinical | https://t.co/QpHRjqbFdk ...
![IMPRES does not reproducibly predict response to immune checkpoint blockade therapy in metastatic melanoma. - Nat. Med. - X-MOL IMPRES does not reproducibly predict response to immune checkpoint blockade therapy in metastatic melanoma. - Nat. Med. - X-MOL](https://xpic.x-mol.com/20191206%2F10.1038_s41591-019-0671-4.png)
IMPRES does not reproducibly predict response to immune checkpoint blockade therapy in metastatic melanoma. - Nat. Med. - X-MOL
![What a massive database of retracted papers reveals about science publishing's 'death penalty' | Science | AAAS What a massive database of retracted papers reveals about science publishing's 'death penalty' | Science | AAAS](https://www.sciencemag.org/sites/default/files/styles/article_main_large/public/Science53-color-1%20horizontal.jpg?itok=GQb_KAEe)
What a massive database of retracted papers reveals about science publishing's 'death penalty' | Science | AAAS
![Metagenomic Analysis of Colorectal Cancer Datasets Identifies Cross-cohort Microbial Diagnostic Signatures and a Link with Choline Degradation | Request PDF Metagenomic Analysis of Colorectal Cancer Datasets Identifies Cross-cohort Microbial Diagnostic Signatures and a Link with Choline Degradation | Request PDF](https://i1.rgstatic.net/publication/332137786_Metagenomic_Analysis_of_Colorectal_Cancer_Datasets_Identifies_Cross-cohort_Microbial_Diagnostic_Signatures_and_a_Link_with_Choline_Degradation/links/5ca37f40a6fdcc12ee8ec36b/largepreview.png)